Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29913938 | 1.00 | EPHX2 (0.60) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL29401765 | 1.00 | EPHX2 (0.60) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL3209124 | 0.92 | EPHX2 (0.55) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL29342668 | 0.90 | EPHX2 (0.57) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL569859 | 0.89 | EPHX2 (0.54) | EPHX2KMT2ACASP3NPC1RAB9A | |
| SCHEMBL8088703 | 0.88 | EPHX2 (0.56) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL15186922 | 0.87 | EPHX2 (0.61) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL3203815 | 0.87 | EPHX2 (0.65) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL6346117 | 0.87 | EPHX2 (0.52) | EPHX2KMT2AFABP7FABP5CHRM3 | |
| SCHEMBL1157612 | 0.86 | EPHX2 (0.57) | EPHX2KMT2AFABP7FABP5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114736131-A | Synthetic method of bromfenac sodium | 郑州灏瑞医药科技有限公司 | 2022-07-12 | — | — | CN | claimed |
| CN-111714480-A | Use of anthranilic acid derivatives in the manufacture of a medicament for the treatment of cancer | 天津贝猫科技有限公司 | 2020-09-29 | — | — | CN | claimed |
| US-20030050248-A1 | Novel amino acid and peptide inhibitors of Staphylococcus virulence | PANORAMA RESEARCH, INC. | 2003-03-13 | — | — | US | claimed |
| EP-1261362-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | Intermune, Inc. (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | claimed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| CN-118084813-A | Macrocyclic compounds | 诺和诺德牛津研究中心有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| CN-110691777-B | Macrocyclic compounds | 诺和诺德牛津研究中心有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-114736131-A | Synthetic method of bromfenac sodium | 郑州灏瑞医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2002036616-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020048763-A1 | Human genome-derived single exon nucleic acid probes useful for gene expression analysis | AMERSHAM PLC (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020048800-A1 | Myosin-like gene expressed in human heart and muscle | GE HEALTHCARE LIMITED (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024718-A1 | COMPOSITIONS AND METHODS RELATING TO PROSTATE SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002024750-A2 | HUMAN KIDNEY TUMOR OVEREXPRESSED MEMBRANE PROTEIN 1 | AEOMICA, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| WO-2001092524-A2 | MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE | AEOMICA, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | EPHX2 4299/4885KMT2A 4690/4885FABP7 2453/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | EPHX2 4299/4885KMT2A 4690/4885FABP7 2453/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | EPHX2 4299/4885KMT2A 4690/4885FABP7 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.